Pall Life Sciences wins BPI 2016 Best Downstream Application Award
Cadence Acoustic Separator system is a novel single-use solution for the clarification of cell culture bioprocess fluids.
Pall Life Sciences, a division of Pall Corporation,has won the BioProcess International (BPI) Award for best downstream processing application for the Cadence Acoustic Separator. Celebrated bi-annually since 2012, the BPI Awards are hosted during the BioProcess International Conference in Boston, MA. The awards exist to celebrate outstanding individual and team achievements that allow the industry to deliver better, more effective treatments to a global patient base.
Based on acoustic wave separation technology licensed from FloDesign Sonics, the Cadence Acoustic Separator was launched in early 2016 as a novel single-use solution for the clarification of cell culture bioprocess fluids. The system is a robust platform technology that enables continuous cell separation without centrifugation and dramatically reduced filtration steps for cost-effective preconditioning of the clarified cell culture fluid for downstream processes. The technology can also be fully integrated with Pall’s portfolio of continuous downstream bioprocessing technologies.
“We are honored by the recognition of the Cadence Acoustic Separator in 2016, but it is particularly exciting to win this award,” said Michael Egholm, VP & General Manager of Pall Biopharmaceuticals. “We first introduced the concept of acoustic wave separation for biopharmaceutical applications at last year’s BPI 2015 conference, with the intention of launching in 2016. Thank you to my team, and the team at FloDesign Sonics for partnering with us to develop and launch such a game-changing technology.”
Earlier this year, the Cadence Acoustic Separator technology was awarded second prize for Innovation in an open vote on submitted posters at the Recovery of Biological Products XVII Conference in Bermuda, as well as featured in Pharmaceutical Manufacturing as a 2016 Star Innovation.
The Cadence Acoustic Separator technology is on display in booth 521 at BPI 2016 this week, among a portfolio of enabling Pall Life Sciences technologies. The displays demonstrate scale up for the clarification application, and a process development approach for perfusion with the AWS technology. Both applications are set to be launched in 2017.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...